Articles published by Atara Biotherapeutics, Inc.

New Landmark Nature Study Provides Long-Sought Mechanistic Link Between EBV and Multiple Sclerosis, Extending Findings from Recent Paper in Science That Identified EBV as the Leading Cause of Multiple Sclerosis

January 24, 2022

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics to Present Recent Progress and Key Upcoming Catalysts at the 40th Annual J.P. Morgan Healthcare Conference

January 10, 2022

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 07, 2022

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 05, 2022

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting

December 13, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021

December 09, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 03, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

European Medicines Agency (EMA) Validates Atara Biotherapeutics' Marketing Authorization Application for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

November 30, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics to Participate at Three Upcoming Investor Conferences

November 08, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 05, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of Tab-cel® Pivotal Phase 3 (ALLELE) Data

November 04, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress

November 04, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021

October 28, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Presents New Magnetization Transfer Ratio Imaging Data and Two-Year Clinical Data from the Open Label Extension of ATA188 for Progressive Multiple Sclerosis at ECTRIMS 2021

October 13, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)

October 04, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

October 01, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021

September 29, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of tab-cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (PTLD)

September 27, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

September 03, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics to Participate in a Panel Discussion at the Citi 16th Annual BioPharma Virtual Conference

September 02, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress

August 09, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Directors

August 09, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 02, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021

August 02, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

July 02, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Joins the Rare Disease Company Coalition Alongside Industry Gamechangers

July 01, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Presents Positive Tab-cel® Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect

June 07, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

June 04, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

May 14, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics to Participate at the Cowen Virtual Oncology Innovation Summit

May 13, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.